dronabinol has been researched along with Non-alcoholic Fatty Liver Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Appendino, G; Carmona-Hidalgo, B; García-Martín, A; González-Mariscal, I; Muñoz, E; Prados, ME; Ruiz-Pino, F; Tena-Sempere, M | 1 |
| Cawthorne, M; Di Marzo, V; Guadagnino, I; Martella, A; Melck, D; Motta, A; Paris, D; Silvestri, C | 1 |
2 other study(ies) available for dronabinol and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Δ9-Tetrahydrocannabinolic Acid markedly alleviates liver fibrosis and inflammation in mice.
Topics: Animals; Cannabis; Carbon Tetrachloride; Diet, High-Fat; Dronabinol; Gene Expression Regulation; Hepatitis; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; NIH 3T3 Cells; Non-alcoholic Fatty Liver Disease; Obesity | 2021 |
Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Cannabidiol; Cannabinoids; Cell Line; Dronabinol; Hepatocytes; Humans; Lipid Metabolism; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Oleic Acid; Receptor, Cannabinoid, CB1; Triglycerides; TRPV Cation Channels; Zebrafish | 2015 |